Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease

Neurobiology of Disease

Volumn 62, Issue , 2014, Pages 31-43

  Camboni, Marybeth ^a   Wang, Chiou Miin ^a   Miranda, Carlos ^a   Yoon, Jung Hae ^a   Xu, Rui ^a   Zygmunt, Deborah ^a   Kaspar, Brian K ^a,b   Martin, Paul T ^a,b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid; Learning; Memory; Neurodegeneration; Peptide mimotope; PSD95; Synapse; Synaptophysin; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BRAIN PROTEIN; P4D6 ANTIBODY; PEPTIDE ANTIBODY; PEPTIDE DERIVATIVE; SDPM1 4E PEPTIDE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IMAGE ANALYSIS; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LEARNING; MALE; MAZE TEST; MEMORY; MORRIS WATER MAZE TEST; MOUSE; NEUROTOXICITY; NONHUMAN; OPEN FIELD TEST; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ALZHEIMER'S DISEASE; AMYLOID; LEARNING; MEMORY; NEURODEGENERATION; PEPTIDE MIMOTOPE; PSD95; SYNAPSE; SYNAPTOPHYSIN; VACCINE;

ALUMINUM HYDROXIDE; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; IMMUNIZATION, PASSIVE; MAZE LEARNING; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PEPTIDES; PLAQUE, AMYLOID; SYNAPSES; TREATMENT OUTCOME; VACCINATION;

EID: 84884962550     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.09.001     Document Type: Article

References (76)

1. Bachman D.L., et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992, 42:115-119.
2. Bard F., et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2023-2028.
3. Barghorn S., et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 2005, 95:834-847.
4. Borchelt D.R., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
5. Buttini M., et al. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 2002, 22:10539-10548.
6. Buttini M., et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:9096-9101.
7. Carty N.C., et al. Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J. Neuroinflammation 2006, 3:11.
8. Chen W.H., et al. Vaccination in the elderly: an immunological perspective. Trends Immunol. 2009, 30:351-359.
9. Cleary J.P., et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
10. Cribbs D.H. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol. Disord. Drug Targets 2010, 9:207-216.
11. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 1990, 27:457-464.
12. Delrieu J., et al. 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J. Neurochem. 2012, 120(Suppl. 1):186-193.
13. DeMattos R.B., et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8850-8855.
14. Finkelman F.D., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 1990, 8:303-333.
15. Ghochikyan A., et al. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine 2006, 24:2275-2282.
16. Gilman S., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
17. Grubeck-Loebenstein B., et al. Immunosenescence and vaccine failure in the elderly. Aging Clin. Exp. Res. 2009, 21:201-209.
18. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
19. Haynes L., Swain S.L. Why aging T cells fail: implications for vaccination. Immunity 2006, 24:663-666.
20. Hock C., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554.
21. Hrncic R., et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am. J. Pathol. 2000, 157:1239-1246.
22. Hsieh H., et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006, 52:831-843.
23. Jankowsky J.L., et al. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 2001, 17:157-165.
24. Jayasinha V., et al. Inhibition of dystroglycan cleavage causes muscular dystrophy in transgenic mice. Neuromuscul. Disord. 2003, 13:365-375.
25. Josefowicz S.Z., et al. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 2012, 30:531-564.
26. Kang C.K., et al. Identification of peptides that specifically bind Abeta1-40 amyloid in vitro and amyloid plaques in Alzheimer's disease brain using phage display. Neurobiol. Dis. 2003, 14:146-156.
27. Kelly K.J., et al. A novel method to determine specificity and sensitivity of the TUNEL reaction in the quantitation of apoptosis. Am. J. Physiol. Cell Physiol. 2003, 284:C1309-C1318.
28. Kim J.H., et al. Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J. Neurosci. 2001, 21:1327-1333.
29. Lace G.L., et al. A brief history of tau: the evolving view of the microtubule-associated protein tau in neurodegenerative diseases. Clin. Neuropathol. 2007, 26:43-58.
30. Lambert M.P., et al. Beta/A4-evoked degeneration of differentiated SH-SY5Y human neuroblastoma cells. J. Neurosci. Res. 1994, 39:377-385.
31. Lambert M.P., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6448-6453.
32. Laskowitz D.T., Kolls B.J. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2010, 74:2026. (author reply 2026-7).
33. Lemere C.A. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog. Brain Res. 2009, 175:83-93.
34. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat. Rev. Neurol. 2010, 6:108-119.
35. Lesne S., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
36. Levites Y., et al. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. 2006, 116:193-201.
37. Levites Y., et al. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J. Neurosci. Official J. Soc. Neurosci. 2006, 26:11923-11928.
38. Marcello E., et al. Synaptic dysfunction in Alzheimer's disease. Adv. Exp. Med. Biol. 2012, 970:573-601.
39. Masliah E., et al. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am. J. Pathol. 1991, 138:235-246.
40. Monsonego A., et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 2003, 112:415-422.
41. Morrissette D.A., et al. Relevance of transgenic mouse models to human Alzheimer disease. J. Biol. Chem. 2009, 284:6033-6037.
42. Nelson P.T., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 2012, 71:362-381.
43. Nicoll J.A., et al. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol. 2006, 65:1040-1048.
44. O'Nuallain B., et al. Phage display and peptide mapping of an immunoglobulin light chain fibril-related conformational epitope. Biochemistry 2007, 46:13049-13058.
45. Orgogozo J.M., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
46. Ostrowitzki S., et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 2012, 69:198-207.
47. Pahlman S., et al. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ. 1984, 14:135-144.
48. Panza F., et al. Immunotherapy for Alzheimer's disease: from anti-beta-amyloid to tau-based immunization strategies. Immunotherapy 2012, 4:213-238.
49. Park S.R., et al. Analysis of transforming growth factor-beta1-induced Ig germ-line gamma2b transcription and its implication for IgA isotype switching. Eur. J. Immunol. 2005, 35:946-956.
50. Pham E., et al. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J. 2010, 277:3051-3067.
51. Pride M., et al. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 2008, 5:194-196.
52. Roher A.E., et al. Neuropathology and amyloid-beta spectrum in a bapineuzumab immunotherapy recipient. J. Alzheimers Dis. 2011, 24:315-325.
53. Savonenko A., et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 2005, 18:602-617.
54. Scheff S.W., Price D.A. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol. Aging 2003, 24:1029-1046.
55. Schenk D. Current challenges for the successful treatment and prevention of Alzheimer's disease: treating the pathologies of the disease to change its clinical course. Alzheimers Dement. 2008, 4:S119-S121.
56. Schenk D., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
57. Schijns V.E., Lavelle E.C. Trends in vaccine adjuvants. Expert Rev. Vaccines 2011, 10:539-550.
58. Schneeberger A., et al. Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing. J. Nutr. Health Aging 2009, 13:264-267.
59. Selkoe D.J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J. Alzheimers Dis. 2001, 3:75-80.
60. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
61. Shankar G.M., et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27:2866-2875.
62. Shankar G.M., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
63. Shankar G.M., et al. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol. Dis. 2009, 36:293-302.
64. Sze C.I., et al. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropathol. Exp. Neurol. 1997, 56:933-944.
65. Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J. Exp. Med. 2010, 220:95-106.
66. Tanaka K., et al. A mimotope peptide of Abeta42 fibril-specific antibodies with Abeta42 fibrillation inhibitory activity induces anti-Abeta42 conformer antibody response by a displayed form on an M13 phage in mice. J. Neuroimmunol. 2011, 236:27-38.
67. Terry R.D. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J. Neuropathol. Exp. Neurol. 1996, 55:1023-1025.
68. Terry R.D., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
69. Tran D.Q. TGF-beta: the sword, the wand, and the shield of FOXP3(+) regulatory T cells. J. Mol. Cell Biol. 2012, 4:29-37.
70. Vaisid T., et al. Amyloid beta peptide toxicity in differentiated PC12 cells: calpain-calpastatin, caspase, and membrane damage. J. Neurosci. Res. 2008, 86:2314-2325.
71. Walsh D.M., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
72. Wang C.M., et al. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2010, 39:409-422.
73. Wei W., et al. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat. Neurosci. 2010, 13:190-196.
74. Wilcock D.M., et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. Official J. Soc. Neurosci. 2003, 23:3745-3751.
75. Yamada K., et al. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J. Neurosci. 2009, 29:11393-11398.
76. Yoon J.H., et al. The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: partial dependence on utrophin. Mol. Cell. Neurosci. 2009, 41:448-463.